Hemoglobinopathies are the first among genetic disorders for which a national guideline for prevention and control has been framed. The elements of the guidelines are guided by WHO directives and guidelines on hemoglobinopathies including Thalassemia and sickle cell disorders and WHO report on services for prevention and management of genetic disorders in developing countries. The NHM guidelines provide a framework based on strategies for prevention and management of hemoglobinopathies documented in publications of Thalassemia International Federation (TIF), various peer reviewed publications, reports of acknowledged groups and on experiences derived from implementing these strategies in public Health set up under NHM.

The guiding elements of NHM Guidelines on Hemoglobinopathies :


Mission: To improve care of all Thalassemia and Sickle Cell Disease patients for their better future and to lower the prevalence of hemoglobinopathies through screening and awareness strategies

NHM Guidelines for Prevention

Based on public health goal of reduction in the prevalence of hemoglobinopathies

Based on the rights of prospective parents at risk of having a child with a serious genetic Disorder

NHM Guidelines for Management of Affected Children

Based on rights of patients for access to care